Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

CDER167, a dual inhibitor of URAT1 and GLUT9, is a novel and potent uricosuric candidate for the treatment of hyperuricemia
Zean Zhao, Jiang Yu, Yanyu Chen, et al.
Acta Pharmacologica Sinica (2021) Vol. 43, Iss. 1, pp. 121-132
Open Access | Times Cited: 34

Showing 1-25 of 34 citing articles:

Emerging Urate-Lowering Drugs and Pharmacologic Treatment Strategies for Gout: A Narrative Review
Robert Terkeltaub
Drugs (2023) Vol. 83, Iss. 16, pp. 1501-1521
Closed Access | Times Cited: 35
Agents for the Treatment of Gout: Current Advances and Future Perspectives
Xiaoyi Zeng, Yajing Liu, Yuxin Fan, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 21, pp. 14474-14493
Closed Access | Times Cited: 24
Discovery of a Novel Thienopyrimidine Compound as a Urate Transporter 1 and Glucose Transporter 9 Dual Inhibitor with Improved Efficacy and Favorable Druggability
Xiaoyu Shi, Tong Zhao, Shuo Wang, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 6, pp. 5032-5052
Closed Access | Times Cited: 9
Review of Urate-Lowering Therapeutics: From the Past to the Future
Christopher Jenkins, Jennifer H. Hwang, Jeffrey B. Kopp, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 36
Pharmacological evaluation of a novel skeleton compound isobavachin (4′,7-dihydroxy-8-prenylflavanone) as a hypouricemic agent: Dual actions of URAT1/GLUT9 and xanthine oxidase inhibitory activity
Zean Zhao, Jian Luo, Hui Liao, et al.
Bioorganic Chemistry (2023) Vol. 133, pp. 106405-106405
Closed Access | Times Cited: 21
Protecting against ferroptosis in hyperuricemic nephropathy: The potential of ferrostatin-1 and its inhibitory effect on URAT1
Yongmei Li, Fengxin Zheng, Shiqi Zhong, et al.
European Journal of Pharmacology (2024) Vol. 971, pp. 176528-176528
Closed Access | Times Cited: 7
Recent Progress and Future Perspectives on Anti-Hyperuricemic Agents
Zhiqiang Sun, Xuewen Zhang, Zean Zhao, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 22, pp. 19966-19987
Closed Access | Times Cited: 7
Hypouricemic and nephroprotective effects of palmatine from Cortex Phellodendri Amurensis: A uric acid modulator targeting Keap1-Nrf2/NLRP3 axis
Gaoxiang Ai, Ronglei Huang, Jianhui Xie, et al.
Journal of Ethnopharmacology (2022) Vol. 301, pp. 115775-115775
Closed Access | Times Cited: 27
Guluronate oligosaccharides exerts beneficial effects on hyperuricemia and regulation of gut microbiota in mice
Biqian Wei, Pengfei Ren, Changhu Xue, et al.
Food Bioscience (2023) Vol. 54, pp. 102855-102855
Closed Access | Times Cited: 14
Discovery of novel verinurad analogs as dual inhibitors of URAT1 and GLUT9 with improved Druggability for the treatment of hyperuricemia
Zean Zhao, Jin Liu, Peihua Kuang, et al.
European Journal of Medicinal Chemistry (2021) Vol. 229, pp. 114092-114092
Closed Access | Times Cited: 32
Lychee Peel Extract Ameliorates Hyperuricemia by Regulating Uric Acid Production and Excretion in Mice
Z. Y. Guo, Li Zhang, Jinlei Liu, et al.
Current Issues in Molecular Biology (2025) Vol. 47, Iss. 2, pp. 76-76
Open Access
Research progress and perspectives of dual-target inhibitors
Xiaojing Pang, Wenyan Xu, Jing Liang, et al.
European Journal of Medicinal Chemistry (2025) Vol. 289, pp. 117453-117453
Closed Access
Prunus mume Alleviates Hyperuricemic Renal Injury: Insights From Network Pharmacology and Experimental Models
ShaoJun Zheng, Sheng Li, Xingxing Diao, et al.
Biomedical Chromatography (2025) Vol. 39, Iss. 4
Closed Access
Dihydromyricetin ameliorates hyperuricemia through inhibiting uric acid reabsorption
Ze‐Rui Sun, H. Peng, Mao‐Si Fan, et al.
Journal of the Science of Food and Agriculture (2025)
Closed Access
Identification of 5-[5-cyano-1-(pyridin-2-ylmethyl)-1H-indole-3-carboxamido] thiazole-4-carboxylic acid as a promising dual inhibitor of urate transporter 1 and xanthine oxidase
Fengwei Lin, Ming Sun, Jun Gao, et al.
European Journal of Medicinal Chemistry (2023) Vol. 257, pp. 115532-115532
Closed Access | Times Cited: 9
Salinomycin, a potent inhibitor of XOD and URAT1, ameliorates hyperuricemic nephropathy by activating NRF2, modulating the gut microbiota, and promoting SCFA production
Yongjun Chen, Zitao Guo, Hai-Qiao Chen, et al.
Chemico-Biological Interactions (2024) Vol. 403, pp. 111220-111220
Closed Access | Times Cited: 3
Oxyberberrubine, a novel liver microsomes-mediated secondary metabolite of berberine, alleviates hyperuricemic nephropathy in mice
Linjiang Zhong, Yinsi Lin, Shiting Gong, et al.
Phytomedicine (2022) Vol. 108, pp. 154521-154521
Closed Access | Times Cited: 14
Anti-hyperuricemia effect of Clerodendranthus spicatus: a molecular biology study combined with metabolomics
Zheng Zhou, Manfei Xu, Meng Bian, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 2
Discovery of a Potent and Orally Bioavailable Xanthine Oxidase/Urate Transporter 1 Dual Inhibitor as a Potential Treatment for Hyperuricemia and Gout
Xinye Yang, Yong Li, Shengqiang Pan, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 16, pp. 14668-14691
Closed Access | Times Cited: 2
Design, synthesis and bioactivity evaluation of isobavachin derivatives as hURAT1 inhibitors for hyperuricemia agents
Zean Zhao, Xinhua Chen, Jiajun Luo, et al.
European Journal of Medicinal Chemistry (2024) Vol. 277, pp. 116753-116753
Closed Access | Times Cited: 2
Novel natural scaffold as hURAT1 inhibitor identified by 3D-shape-based, docking-based virtual screening approach and biological evaluation
Xinhua Chen, Zean Zhao, Jiajun Luo, et al.
Bioorganic Chemistry (2021) Vol. 117, pp. 105444-105444
Closed Access | Times Cited: 15
Discovery of novel benzbromarone analogs with improved pharmacokinetics and benign toxicity profiles as antihyperuricemic agents
Zean Zhao, Jin Liu, L. Yuan, et al.
European Journal of Medicinal Chemistry (2022) Vol. 242, pp. 114682-114682
Closed Access | Times Cited: 11
Hypouricemic effect of 2,4-dihydroxybenzoic acid methyl ester in hyperuricemic mice through inhibiting XOD and down-regulating URAT1
Tianqiao Yong, Danling Liang, Chun Xiao, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 153, pp. 113303-113303
Open Access | Times Cited: 10
Recent Updates of Natural and Synthetic URAT1 Inhibitors and Novel Screening Methods
Ying Chen, Ruya You, Ke Wang, et al.
Evidence-based Complementary and Alternative Medicine (2021) Vol. 2021, pp. 1-12
Open Access | Times Cited: 11
Mutation in Transmembrane Domain 8 of Human Urate Transporter 1 Disrupts Uric Acid Recognition and Transport
Qunsheng Lan, Zean Zhao, Hui Liao, et al.
ACS Omega (2022) Vol. 7, Iss. 38, pp. 34621-34631
Open Access | Times Cited: 8
Page 1 - Next Page

Scroll to top